Back to News
Market Impact: 0.3
Haemonetics Reports Q2 Fiscal 2027 Results; Raises Full-Year Revenue And Organic Growth Outlook
Source: Nasdaq
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Haemonetics reported second-quarter fiscal 2027 results, with revenue growth in its Apheresis and MedSurg businesses. The company also raised its full-year outlook; the supplied article text is truncated and provides no figures or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
HAE0.65
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook